Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Accolade reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Accolade announced earnings per share of $-0.66 on revenue of $87.64M. Analysts polled by Investing.com EPS of $-0.72 on revenue of $82.87M.
Accolade 's are down 53% and is trading at $11.92 , still down 70.02% from its 52 week high of $41.33 set on Thursday, October 7, 2021.
Accolade shares lost 3.79% to trade at $11.92 in after-hours trade the report.
Accolade follows other major Healthcare sector earnings this month
Accolade's report follows an earnings beat by Merck ADR on Friday, September 9, 2022, who reported EPS of $0.5392 on revenue of $5.69B, EPS of $0.5165 on revenue of $5.57B.
Carl Zeiss Meditec ADR had beat expectations on Friday, September 9, 2022 with third quarter EPS of $0.7134 on revenue of $486.54M, for EPS of $0.7116 on revenue of $486.31M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar